WestEnd Advisors’s Moderna MRNA Stock Holding History

WestEnd Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17K	Buy	31 +4	+15%	+$207	﹤0.01%	181
2026 Q1	$1.37K	Hold	27	–	–	﹤0.01%	193
2025 Q4	$796	Buy	27 +15	+125%	+$408	﹤0.01%	266
2025 Q3	$310	Sell	12 -2	-14%	-$56	﹤0.01%	354
2025 Q2	$386	Buy	14 +1	+8%	+$26	﹤0.01%	303
2025 Q1	$369	Buy	13 +9	+225%	+$319	﹤0.01%	297
2024 Q4	$166	Hold	4	–	–	﹤0.01%	279
2024 Q3	$267	Hold	4	–	–	﹤0.01%	258
2024 Q2	$475	Sell	4 -1	-20%	-$127	﹤0.01%	165
2024 Q1	$533	Hold	5	–	–	﹤0.01%	149
2023 Q4	$497	Hold	5	–	–	﹤0.01%	160
2023 Q3	$516	Buy	+5	New	+$558	﹤0.01%	150
2023 Q1	–	Sell	-4	Closed	-$660	–	138
2022 Q4	$718	Hold	4	–	–	﹤0.01%	122
2022 Q3	$0	Hold	4	–	–	﹤0.01%	267
2022 Q2	$571	Buy	+4	New	+$572	﹤0.01%	131
2022 Q1	–	Sell	-3	Closed	-$505	–	148
2021 Q4	$761	Buy	+3	New	+$877	﹤0.01%	123
2021 Q3	–	Hold	0	–	–	–	93

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

WestEnd Advisors's MRNA Position: Q2 2026 in Review

WestEnd Advisors increased its Moderna (MRNA) stake by 15% in Q2 2026, buying an estimated $207 and bringing the position to 31 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #181.

WestEnd Advisors first reported a position in MRNA in Q4 2021 and has held it in 16 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

WestEnd Advisors held 31 shares of Moderna worth $2.17K as of Q2 2026.
WestEnd Advisors bought 4 Moderna shares in Q2 2026, an estimated $207.
Moderna made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #181 holding.
WestEnd Advisors first reported a position in Moderna in Q4 2021 and has held it in 16 quarters since.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.